(June 16, 2021) Lumosa Therapeutics Co., Ltd. (Lumosa, code: 6535.TWO) announced today the granting of formulation patent for its extended-release analgesic injection, LT1001 (brand name: Naldebain®), the patent is valid until 2036. China is a market with considerable sales potential for LT1001. The patent adds value to the product while creating barriers against future competition. A phase 3 trial has already been initiated in China and is expected to be completed in 2022, an NDA will be submitted soon afterward.

LT1001 is the first new drug developed by Lumosa that has reached the global market with the potential of generating steady working capital. Besides approvals from Taiwan and Singapore, Lumosa is striving to obtain approvals from other ASEAN countries such as Thailand and Malaysia. Further, Lumosa actively searches for regional licensing opportunities while focuses on building a comprehensive patent layout. Patent applications were submitted to 20 countries and approvals from the US, Russia, Taiwan, India, Singapore, and China have been received. Patent application in other major pharmaceutical markets such as European Community, Japan, and other states is still underway. Other than successful licensing of China and Southeast Asia, Lumosa takes additional steps seeking business collaborations and promotional opportunities of LT1001 in the US and Korea.

LT1001 is the world’s first week-long extended-release analgesic injection. The long-acting effect, good safety profile, and convenient medication regime, as well as low substance dependence potential, are unique features that give LT1001 an edge over other opioid products.